The reduction in price target by a major financial institution like Morgan Stanley suggests a negative outlook on Veracyte's stock performance in the short term. Investors often take cues from analyst ratings and price targets, which can influence stock price movements. The Underweight rating and lowered price target could lead to a decrease in investor confidence and a potential decline in the stock price.